Document is current
Any future updates will be listed below
-
Authors
Hamdan, Firas https://orcid.org/0000-0003-4678-7382
Gandolfi, Sara https://orcid.org/0000-0001-6207-4433
D’Alessio, Federica
Giannoula, Yvonne https://orcid.org/0000-0003-4265-5411
Kolikova, Julia
Fusciello, Manlio https://orcid.org/0000-0002-7166-3018
Zaghen, Elisa https://orcid.org/0009-0006-6665-296X
Napolano, Alessandra
Russo, Salvatore
Izci, Ozan
Bottega, Paolo
Chiaro, Jacopo https://orcid.org/0000-0001-6577-2691
Alanen, Kirsi-Marja https://orcid.org/0009-0002-0068-6850
Antignani, Gabriella
Feodoroff, Michaela https://orcid.org/0000-0002-6094-9838
Stigzelius, Virpi
Sakalauskaite, Milda
Sandberg, Janita
Nieminen, Anni I. https://orcid.org/0000-0001-8999-6040
Zambrano, Nicola
Eriksson, Ove
Mustjoki, Satu https://orcid.org/0000-0002-0816-8241
Seppälä, Toni T.
Grönholm, Mikaela
Cerullo, Vincenzo https://orcid.org/0000-0003-4901-3796
-
Funding
Funding for this research was provided by:
Jane ja Aatos Erkon Säätiö (4705796)
- License Information
-
More Information
Article History
Received: 16 April 2025
Accepted: 8 January 2026
First Online: 28 January 2026
Competing interests
: V.C. is co-founder and shareholder of Valo Therapeutics LTD. H.C. and L.K. are stakeholders of Valo Therapeutics LTD. Toni T. Seppälä reports consultation fees from Mehiläinen, Nouscom, Orion Pharma, Amgen, and Tillots Pharma, and a position in the Clinical Advisory Board and as a minor shareholder of Lynsight Ltd. S.M. has received honoraria and research funding from Novartis, Pfizer, and Bristol-Myers Squibb and honoraria from Dren-Bio (not related to this study). V.S. is an employee and shareholder of AstraZeneca. All other named authors declare that they have no competing interests, financial or otherwise.
